Compare SLN & TCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLN | TCI |
|---|---|---|
| Founded | 1994 | 1983 |
| Country | United Kingdom | United States |
| Employees | 116 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.2M | 343.6M |
| IPO Year | N/A | 1994 |
| Metric | SLN | TCI |
|---|---|---|
| Price | $5.75 | $36.23 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $39.67 | N/A |
| AVG Volume (30 Days) | ★ 168.0K | 1.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.64 |
| Revenue | N/A | ★ $47,070,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $56.31 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.97 | $26.96 |
| 52 Week High | $7.78 | $59.65 |
| Indicator | SLN | TCI |
|---|---|---|
| Relative Strength Index (RSI) | 59.50 | 25.34 |
| Support Level | $5.07 | $26.96 |
| Resistance Level | $6.10 | $47.17 |
| Average True Range (ATR) | 0.49 | 1.60 |
| MACD | 0.16 | -1.47 |
| Stochastic Oscillator | 65.37 | 2.76 |
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates multifamily and commercial properties throughout the southern United States and also invests in mortgage notes receivable and in the land that is either held for appreciation or development. The company has two business segments: the acquisition, development, ownership, and management of multifamily properties which include the rental of apartments (Residential Segment) and other tenant services, including parking and storage space rental, and the acquisition, development, ownership, and management of commercial properties which are office properties(Commercial Segment). It includes the rental of office space and other tenant services, including parking and storage space rental.